Molecular Inflammation Board for personalized care of chronic inflammatory diseases
The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
University Hospital Tuebingen · NCT07132333
This project collects clinical, lab, imaging, and patient-reported data from adults with psoriasis, psoriatic arthritis, spondyloarthritis, or inflammatory bowel disease who are referred to the Molecular Inflammation Board to see if the board's recommendations influence care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Tuebingen (other) |
| Locations | 1 site (Tübingen) |
| Trial ID | NCT07132333 on ClinicalTrials.gov |
What this trial studies
This is a prospective, observational program that documents all patients referred to the Molecular Inflammation Board at the Center for Personalized Medicine. It captures clinical outcomes, peripheral immune monitoring, imaging parameters, patient-reported outcomes, and records whether clinicians follow the board's recommendations. The effort is coordinated at University Hospital Tübingen with collaboration from University Hospitals Freiburg, Heidelberg, and Ulm. No experimental treatment is assigned by the program; biologic therapies used in routine care are recorded and analyzed.
Who should consider this trial
Good fit: Adults (18 years or older) with a chronic inflammatory disorder (psoriasis, psoriatic arthritis, spondyloarthritis, Crohn's disease, or ulcerative colitis) who are referred to the Molecular Inflammation Board and can give informed consent.
Not a fit: Patients who are not referred to the Molecular Inflammation Board or who lack the capacity to give informed consent will not be included and therefore will not directly benefit from the program's data-driven recommendations.
Why it matters
Potential benefit: If successful, this work could help tailor treatments more precisely and improve outcomes by identifying which board-guided recommendations lead to better patient results.
How similar studies have performed: Multidisciplinary molecular or inflammation boards and prospective registries have shown promise in improving personalized care in related fields, but robust outcome data specific to this approach in chronic inflammatory diseases remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic inflammatory disorder (PsO, PsA, SpA, IBD) * Given informed consent * 18 years of age Exclusion Criteria: * No capacity to consent
Where this trial is running
Tübingen
- University Hospital of Tübingen - Center for Personalized Medicine — Tübingen, Germany (RECRUITING)
Study contacts
- Study coordinator: Nisar P Malek, Prof. Dr.
- Email: zpm-meb@med.uni-tuebingen.de
- Phone: +4970712982722
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Psoriasis, Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn', s Disease and Ulcerative Colitis), Spondylarthropathies, chronic inflammatory diseases, personalized medicine